Literature DB >> 20823096

Lysophosphatidic acid-activated Cl- current activity in human systemic sclerosis skin fibroblasts.

Zhaohong Yin1, Laura D Carbone, Mari Gotoh, Arnold Postlethwaite, Alyssa L Bolen, Gabor J Tigyi, Kimiko Murakami-Murofushi, Mitchell A Watsky.   

Abstract

OBJECTIVES: SSc (scleroderma) is an often fatal disease characterized by widespread tissue fibrosis. Fibroblasts play a key role in SSc-associated fibrosis. This study was designed to determine: (i) whether fibroblasts isolated from skin of patients with SSc have increased lysophosphatidic acid-activated Cl- current (IClLPA) activity vs healthy controls; (ii) whether myofibroblast differentiation is involved in SSc skin fibrosis; and (iii) whether SSc fibroblasts have different proliferation rates vs controls.
METHODS: Skin biopsies were taken from involved and uninvolved skin of SSc patients and controls. Whole-cell perforated patch-clamping was used to measure IClLPA activity in fibroblasts isolated and cultured from these biopsies. Western blotting was used to measure α-smooth muscle actin (α-SMA). Proliferation was measured using a colorimetric assay.
RESULTS: Fibroblasts cultured from SSc skin show significantly increased IClLPA activity following LPA exposure compared with control skin fibroblasts. α-SMA protein was significantly increased in cultured SSc skin fibroblasts vs controls. No significant differences in proliferation rates were found.
CONCLUSIONS: Elevated IClLPA activity is a hallmark of SSc skin fibroblasts. Blocking IClLPA activation may be a new therapeutic approach for treating SSc-associated fibrosis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20823096      PMCID: PMC2981513          DOI: 10.1093/rheumatology/keq260

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  42 in total

Review 1.  Fibroblast and endothelial apoptosis in systemic sclerosis.

Authors:  Jae-Bum Jun; Melanie Kuechle; John M Harlan; Keith B Elkon
Journal:  Curr Opin Rheumatol       Date:  2003-11       Impact factor: 5.006

Review 2.  The myofibroblast in wound healing and fibrocontractive diseases.

Authors:  G Gabbiani
Journal:  J Pathol       Date:  2003-07       Impact factor: 7.996

3.  Dermal mast cell degranulation in systemic sclerosis.

Authors:  J R Seibold; R C Giorno; H N Claman
Journal:  Arthritis Rheum       Date:  1990-11

4.  Management of leg ulcers in patients with rheumatoid arthritis or systemic sclerosis: the importance of concomitant arterial and venous disease.

Authors:  J Hafner; E Schneider; G Burg; P C Cassina
Journal:  J Vasc Surg       Date:  2000-08       Impact factor: 4.268

5.  Lysophosphatidic acid interacts with transforming growth factor-beta signaling to mediate keratinocyte growth arrest and chemotaxis.

Authors:  Bettina Sauer; Rüdiger Vogler; Karsten Zimmermann; Makiko Fujii; Mario B Anzano; Monika Schäfer-Korting; Anita B Roberts; Burkhard Kleuser
Journal:  J Invest Dermatol       Date:  2004-11       Impact factor: 8.551

6.  Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee.

Authors: 
Journal:  Arthritis Rheum       Date:  1980-05

Review 7.  Cytokine regulation of pulmonary fibrosis in scleroderma.

Authors:  Sergei P Atamas; Barbara White
Journal:  Cytokine Growth Factor Rev       Date:  2003-12       Impact factor: 7.638

8.  Platelet-derived growth factor-BB and lysophosphatidic acid distinctly regulate hepatic myofibroblast migration through focal adhesion kinase.

Authors:  Pisit Tangkijvanich; Andrew C Melton; Taned Chitapanarux; Jiu Han; Hal F Yee
Journal:  Exp Cell Res       Date:  2002-11-15       Impact factor: 3.905

9.  LPA1 receptor activation promotes renal interstitial fibrosis.

Authors:  Jean-Philippe Pradère; Julie Klein; Sandra Grès; Charlotte Guigné; Eric Neau; Philippe Valet; Denis Calise; Jerold Chun; Jean-Loup Bascands; Jean-Sébastien Saulnier-Blache; Joost P Schanstra
Journal:  J Am Soc Nephrol       Date:  2007-11-14       Impact factor: 10.121

10.  Receptor-mediated activation of a Cl(-) current by LPA and S1P in cultured corneal keratocytes.

Authors:  Jia Wang; Laura D Carbone; Mitchell A Watsky
Journal:  Invest Ophthalmol Vis Sci       Date:  2002-10       Impact factor: 4.799

View more
  6 in total

Review 1.  Pathogenesis of Systemic Sclerosis.

Authors:  Debendra Pattanaik; Monica Brown; Bradley C Postlethwaite; Arnold E Postlethwaite
Journal:  Front Immunol       Date:  2015-06-08       Impact factor: 7.561

Review 2.  Targeted therapies for systemic sclerosis.

Authors:  Christopher P Denton; Voon H Ong
Journal:  Nat Rev Rheumatol       Date:  2013-04-09       Impact factor: 20.543

Review 3.  LPA receptor signaling: pharmacology, physiology, and pathophysiology.

Authors:  Yun C Yung; Nicole C Stoddard; Jerold Chun
Journal:  J Lipid Res       Date:  2014-03-18       Impact factor: 5.922

4.  Vascular involvement in systemic sclerosis (scleroderma).

Authors:  Debendra Pattanaik; Monica Brown; Arnold E Postlethwaite
Journal:  J Inflamm Res       Date:  2011-07-26

5.  Antifibrotic effects of 2-carba cyclic phosphatidic acid (2ccPA) in systemic sclerosis: contribution to the novel treatment.

Authors:  Tomoaki Higuchi; Kae Takagi; Akiko Tochimoto; Yuki Ichimura; Takanari Norose; Yasuhiro Katsumata; Ikuko Masuda; Hisashi Yamanaka; Toshiro Morohoshi; Yasushi Kawaguchi
Journal:  Arthritis Res Ther       Date:  2019-04-18       Impact factor: 5.156

Review 6.  The role of antifibrotic therapies in the treatment of systemic sclerosis-associated interstitial lung disease.

Authors:  Gonçalo Boleto; Jérôme Avouac; Yannick Allanore
Journal:  Ther Adv Musculoskelet Dis       Date:  2022-01-29       Impact factor: 3.625

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.